Geron Corporation (GERN) Receives $3.75 Consensus Price Target from Brokerages

Geron Corporation (NASDAQ:GERN) has been assigned an average rating of “Hold” from the six research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $3.75.

A number of equities analysts have recently weighed in on GERN shares. Zacks Investment Research downgraded Geron Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Needham & Company LLC restated a “hold” rating on shares of Geron Corporation in a research note on Friday. Stifel Nicolaus restated a “hold” rating and issued a $2.50 target price on shares of Geron Corporation in a research note on Friday. Finally, BidaskClub downgraded Geron Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th.

Several large investors have recently bought and sold shares of the stock. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Geron Corporation by 1.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 58,056 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 1,000 shares during the period. Creative Planning raised its holdings in shares of Geron Corporation by 1.3% in the 2nd quarter. Creative Planning now owns 103,213 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 1,345 shares during the period. IHT Wealth Management LLC bought a new stake in shares of Geron Corporation in the 2nd quarter worth approximately $122,000. Tudor Investment Corp ET AL raised its holdings in shares of Geron Corporation by 12.1% in the 1st quarter. Tudor Investment Corp ET AL now owns 52,369 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 5,669 shares during the period. Finally, American International Group Inc. raised its holdings in shares of Geron Corporation by 7.1% in the 1st quarter. American International Group Inc. now owns 92,964 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 6,140 shares during the period. 38.78% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/11/05/geron-corporation-gern-receives-3-75-consensus-price-target-from-brokerages.html.

Shares of Geron Corporation (NASDAQ GERN) traded up $0.07 during midday trading on Thursday, hitting $2.12. The stock had a trading volume of 935,088 shares, compared to its average volume of 1,275,479.

Geron Corporation (NASDAQ:GERN) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Geron Corporation had a negative return on equity of 25.14% and a negative net margin of 2,992.67%. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.40 million. During the same quarter in the previous year, the business earned ($0.02) EPS. The company’s revenue was down 96.8% compared to the same quarter last year. analysts forecast that Geron Corporation will post -0.17 earnings per share for the current year.

About Geron Corporation

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

What are top analysts saying about Geron Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Geron Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit